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Abstract  
Diet influences the composition of the gut microbiota and host’s health, particularly in 
patients suffering from food-related diseases. Celiac disease (CD) is a permanent 
intolerance to cereal gluten proteins and the only therapy for the patients is to adhere to a 
life-long gluten-free diet (GFD). Herein, a preliminary study of the effects of a GFD on the 5 
composition and immune properties of the gut microbiota have been analysed in ten healthy 
subjects (30.3 years old) over one month. Faecal microbiota was analyzed by fluorescence 
in situ hybridization (FISH) and quantitative PCR (qPCR). The ability of faecal bacteria to 
stimulate cytokine production by peripheral blood mononuclear cells (PBMCs) was 
determined by ELISA. No significant differences in dietary intake were found before and 10 
after the GFD except for reductions (P=0.001) in polysaccharides. Bifidobacterium, 
Clostridium lituseburense and Faecalibacterium prausnitzii proportions decreased 
(P=0.007, 0.031 and 0.009, respectively) as a result of the GFD analysed by FISH. 
Bifidobacterium, Lactobacillus and B. longum counts decreased (P=0.020, P=0.001 and 
P=0.017, respectively), while Enterobacteriaceae and E. coli counts increased (P=0.005 15 
and P=0.003) after the GFD assessed by qPCR. TNF-α, IFN-γ, IL-10 and IL-8 production 
by PBMCs stimulated with faecal samples was also reduced (P=0.021, P=0.037, P =0.002 
and P =0.007, respectively) after the diet. Therefore, the GFD led to reductions in 
beneficial gut bacteria populations and the ability of faecal extracts to stimulate host’s 
immunity. Thus, the GFD may constitute an environmental variable to be considered in 20 
treated CD patients for its possible effects on gut health.   
 





Diet influences the composition and function of the gut microbiota and, thereby host’s 
health, particularly in patients suffering from food-related diseases. Celiac disease (CD) is 
an inflammatory disorder of the small intestine caused by a permanent intolerance to gluten 
proteins in predisposed individuals. In these patients, gluten peptides trigger an abnormal 5 
immune response that causes the typical CD tissue lesion characterized by villous atrophy, 
crypt hyperplasia, and increased numbers of intraepithelial and lamina propria 
lymphocytes(1-2). CD enteropathy is sustained by a Th1 immune response with production 
of pro-inflammatory cytokines (e.g. IFN-γ), as well as by an innate immune response 
mediated by interleukine (IL)-15 that activate intraepithelial lymphocytes and epithelial cell 10 
killing(3). Increased production of pro-inflammatory cytokines by cells of the innate 
immune system (monocytes, macrophages and dendritic cells) is also thought to mediate 
the recruitment of lymphocytes into the lamina propria and epithelium, thus contributing to 
the disease(4). The treatment with a gluten-free diet (GFD) usually leads to normalization of 
mucosal histology and remission of clinical symptoms. Nevertheless, compliance with this 15 
dietary therapy is very complex and patients often suffer from higher health risks and 
nutritional deficiencies (5-6). The composition and metabolic activity of the intestinal 
microbiota is currently thought to be involved in a number of chronic inflammatory 
disorders. Most recent studies indicate that CD patients untreated and treated with a GFD 
have an unbalanced microbiota that can play a pathogenic role or constitute a risk factor for 20 
this disorder(7-8). Nevertheless, part of the detected microbial changes could be due not only 
to the underlying disease but also to the dietary intervention by a GFD in treated CD 
patients. GFD has also been tested as dietary treatment for autism(9). However, the possible 
effect of a GFD in the gut ecosystem remains largely unknown.  
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The objective of this work was to analyse the impact of a GFD on the composition and 
immune function of the microbiota in healthy subjects to gain further insights on 
interactions between diet and gut microbes, as well as on the possible effects of this therapy 




Ten volunteers (8 women and 2 men; mean age: 30.3 years; range: 23-40 years) were 
included in the study. All participants included in this study have no history of digestive 
pathology or sings of malnutrition. None of the volunteers were treated with antibiotics at 10 
least within the 2 months prior to the faecal sampling. Informed consent was obtained from 
the subjects, and the study was approved by the local Ethics Committee. 
 
Dietary intervention and assessments 
Subjects were submitted to a GFD by replacing gluten-containing foods by equivalent ones 15 
certified as gluten-free (20 ppm maximum gluten content) by the Spanish federation of 
coeliac association (FACE) over 1 month period. Food diary records were kept for 72h (2 
weekdays and 1 weekend day) both before the start of the intervention and after 1 month to 
monitor dietary changes. At the front of the diary, detailed information on how to record 
food and beverages consumed using common household measures was provided. When 20 
completing the food diary records, subjects were instructed to record everything they ate or 
drank. Food diary records were returned to the dietician as soon as possible after 
completion when they were reviewed, and analyzed for energy, water and macronutrient 
contents based on the CESNID food-composition database of Spanish foods (10). 
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Faecal sampling 
Faecal samples from each adult volunteer were collected before and after following a GFD 
and processed as describe elsewhere in duplicate (7, 11). Briefly, 2 g (wet weight) were 10-
fold diluted in phosphate-buffered saline PBS (130 mM sodium chloride, 10mM sodium 
phosphate, pH 7.2) and homogenized for 5 min in a Lab Blender 400 stomacher (Seward 5 
Medical London, UK). The homogenized samples were subjected to a low-spin 
centrifugation (2, 000 rpm, 2 min) to remove large particulate material, and aliquots of the 
obtained supernatants were used for either DNA extraction or hybridisation. Prior 
hybridisation, one volume of the supernatant was mixed with three volumes of fresh 4% 
paraformaldehyde (PFA), fixed at 4°C overnight, and stored in 50% ethanol–PBS at −80 °C 10 
until use for hybridisation(7, 11). DNA extractions were done by using the QIAamp DNA 
stool Mini kit (Qiagen, Hilden, Germany) following the manufacturer’s instructions.  
 
Fluorescence in situ hybridization (FISH) and flow cytometry detection (FCM) 
Enumeration of bacteria present in faecal samples was carried by fluorescence in situ 15 
hybridization (FISH) using 16S rRNA-targeted oligonucleotide probes (MOLBIOL, Berlin, 
Germany), as previously described(7, 11). The following probes were used: EUB 338, for  
detection of total bacteria(12), Ato291 for Atopobium group(13), Bif164 for Bifidobacterium 
genus(14), Lab158 for Lactobacillus and other lactic acid bacteria(15), Bac303 for 
Bacteroides-Prevotella group(16), Ecol1513 for Escherichia coli(17), Erec0482 for 20 
Eubacterium rectale-Clostridium coccoides group(18), CHis159 for Clostridium 
histolyticum group(13), CLis135 for Clostridium lituseburense group(19), Fprau645 for 
Faecalibacterium prausnitzii(20). Cells were enumerated by combining in the same 
hybridization tube, one group specific FITC-probe with the EUB 338-Cy3 probe. The 
proportion of group cells was corrected by eliminating background fluorescence, which 25 
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was measured using the negative control NON 338 probe(7, 21). Fixed cells were incubated 
in the hybridization solution (10 mM Tris-HCl, 0.9 M NaCl, pH 8.0 and 10% SDS) 
containing 4 ng/µl of each fluorescent probe at appropriate temperatures overnight, washed 
and resuspended in PBS solution for flow cytometric analysis(7,11). 
Flow cytometry detections were performed using an EPICS® XL-MCL flow cytometer 5 
(Beckman Coulter, Florida, USA) as previously described(7, 22). This instrument is equipped 
with two light scatter detectors that measure forward (FSC) and side scatter (SSC) and 
fluorescence detectors that detect appropriately filtered light at green (FL1, 525 nm) and 
red-orange (FL3, 620 nm) wavelengths. The event rate was kept at the lowest setting (200-
300 events per second) to avoid cell coincidence. A total of 15, 000 events were recorded in 10 
a list mode file and analyzed with the System II V.3 software (Beckman Coulter). The 
proportion of each bacterial group was expressed as a ratio of cells hybridising with the 
FITC-labelled specific probe to cells hybridising with the universal EUB 338-Cy3 
probe(22,7). 
Quantitative real-time PCR (qPCR) analysis 15 
qPCR was used to characterize the composition of the faecal microbiota by use of specific 
primers targeting different intestinal bacterial groups as described elsewhere (23, 24). PCR 
amplification and detection were performed with an ABI PRISM 7000-PCR sequence 
detection system (Applied Biosystems, UK). Each reaction mixture of 25 µl was composed 
of SYBR® Green PCR Master Mix (SuperArray Bioscience Corporation, USA), 1 µl of 20 
each of the specific primers at a concentration of 0.25 µM, and 1 µl of template DNA. 
Bacterial concentration from each sample was calculated by comparing the Ct values 
obtained from standard curve. Standard curves were created using serial 10-fold dilution of 
pure cultures DNA corresponding to 102 to 109 cells as determined by microscopy counts 
using DAPI.  25 
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Isolation and stimulation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized peripheral 
blood of four healthy volunteers (26-28 years old) as previously described(25). Briefly, 
PBMCs were isolated by centrifugation over a Ficoll density gradient (Amersham 
Biosciences, Piscataway, NJ) and adjusted to 1 × 106 cells/ml in RPMI 1640 (Cambrex, 5 
New York, USA), supplemented with 10% foetal bovine serum (Gibco, Barcelona, Spain), 
2 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin (Sigma).  PBMCs 
were incubated in 24 well flat-bottom polystyrene microtitre plates (Corning, Madrid, 
Spain) and incubated at 37º C under 5% CO2. 30 µl of faecal samples of each subject 
before and after following a GFD were use to stimulate PBMCs for 24 h. Purified 10 
lipopolysaccharide (LPS) from E. coli O111:B4 (Sigma, St. Louis, MO) was used at a 
concentration of 1 µg/ml as a positive control. Non-stimulated PBMCs were also evaluated 
as controls of basal cytokine production. All reagents were tested by the E-toxate test for 
LPS (Sigma) and shown to be below the limit of detection (2 pg/ml). Every sample used as 
stimulant was assayed in duplicated. Cell cultures supernatants were collected by 15 
centrifugation, fractionated in aliquots, and stored at -20ºC until cytokines were analysed. 
 
Cytokines assays  
Cytokine concentrations of supernatants were measured by enzyme-linked immunosorbent 
assay (ELISA). The pro-inflammatory cytokines TNF-α and IFN-γ, and the regulatory 20 
cytokine IL-10 were analysed by using the Ready SET Go! Kit (eBioscience, San Diego, 
CA), and the chemokyne IL-8 by using Diaclone ELISA commercial kit (Madrid, Spain), 
according to the manufacturer's instructions. The sensitivity of assays for each cytokine was 




Statistical analyses were done using the SPSS 11.0 software (SPSS Inc, Chicago, IL, USA). 
Dietary composition (means and standard deviations) were calculated for crude 
(unadjusted) nutrients from the 72 h dietary registers and data were averaged for the 
analysis. Dietary variables were submitted to log-transformation and mean comparisons 5 
before and after the intervention were determined by applying the Student’s t test. 
Microbial data are expressed as medians with interquartile ranges (IQR) and the differences 
in bacterial counts before and after gluten-free diet were determined by applying the Mann-
Whitney U test. Results of cytokine production are expressed as means with standard 
deviations and differences were determined by applying the Student’s t-test. In every case, 10 
P-values <0.050 were considered statistically significant. 
 
Results and discussion 
GFD influences the composition of the intestinal microbiota in healthy subjects 
A preliminary study has been carried out to establish the effects of a GFD on the 15 
composition of the intestinal microbiota and to gain insights into the possible relation of 
this dietary therapy with gut health. The adult human subjects included in the study, 80% 
female (8/10) and 20% male (2/10), maintained a good health status during the 
intervention, and followed a conventional diet without any restriction except for gluten 
containing products. Dietary data before and after the intervention are shown in Table 1. 20 
No significant differences in dietary intake were found in energy and macronutrients as a 
result of the GFD except for significant reductions (P=0.001) in polysaccharide intake. 
Previous studies on the nutritional quality of the GFD also indicated that it is associated 
with reductions in the intake of polysaccharides together with energy compared with the 
standard gluten-containing diet of healthy individuals, according to our results(26). The 25 
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composition of the faecal microbiota under the effects of the GFD determined by FISH is 
shown in Table 2. Individual baseline variability of bacterial populations expressed as 
median of differences in proportions of bacterial cells hybridising with group-specific 
probes related to total bacteria hybridising with EUB probe 338 was as follows: 2.38 (1.01-
5.30) for Atopobium group, 1.86 (1.42-3.10) for Bifidobacterium, 1.54 (1.09-2.13) for 5 
Lactobacillus group, 2.16 (0.86-3.26) for Bacteroides-Prevotella, 1.29 (0.84-1.47) for E. 
coli, 6.54 (0.21-10.41) for E. rectale-C coccoides, 1.04 (0.41-2.48) for C.  histolyticum, 
1.63 (0.59-3.61) for C. lituseburense and 6.65 (0.62-6.72) for F. prausnitzii. 
Bifidobacterium, C. lituseburense and F. prausnitzii proportions decreased significantly 
(P=0.007, 0.031 and 0.009, respectively) as a result of the GFD (Table 2). Lactobacillus 10 
group proportions were also almost significantly reduced (P=0.058) after the GFD (Table 
2). Bacteroides-Prevotella, E. rectale-C. coccoides and C. histolyticum group proportions 
were slightly reduced, while those of E. coli were increased after the GFD but not 
significantly (Table 2). Total counts determined by FISH using DAPI also showed 
significant reductions after the GFD from 10.25 to 9.98 log cell/g faeces (P=0.030). The 15 
composition of the faecal microbiota analysed by qPCR is shown in Table 3. Individual 
baseline variability of bacterial populations expressed as median of differences in log cells 
per gram of faeces (IQR) was as follows: 0.37 (0.17-0.65) for Bifidobacterium, 1.50 (0.21-
1.68) for Bacteroides,   0.40 (0.08-0.82) for C. coccoides, 0.27 (0.13-1.05) for C. leptum, 
0.27 (0.33-0.37) for C. histolyticum, 0.87 (0.20-1.13) for Lactobacillus, 0.48 (0.24-1.18) for 20 
E. coli,  and 0.80 (0.15-1.37) for Enterobacteriaceae. The counts of Bifidobacterium and 
Lactobacillus groups decreased significantly after GFD (P=0.020 and P=0.001, 
respectively), while E. coli (P=0.003) and total Enterobacteriaceae counts significantly 
increased (P=0.005) as a result of the GFD, following a similar trend as that detected by 
FISH. Total counts were also reduced after the GFD when determined by qPCR from 9.85 25 
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to 9.71 log cell/g faeces (P=0.089) following the same trend as by FISH quantification. 
Therefore, introduction of a GFD implied a reduction in bacterial populations generally 
regarded as beneficial for human health such as Bifidobacterium and Lactobacillus, and an 
increase in those of opportunistic pathogens such as E. coli and total Enterobacteriaceae. 
These changes could be related to reductions in polysaccharide intake since these dietary 5 
compounds usually reach the distal part of the colon partially undigested, and constitute 
one of the main energy sources for beneficial components of the gut microbiota(27). In 
addition, reductions in Bifidobacterium and Lactobacillus populations relative to Gram-
negative bacteria (Bacteroides and E. coli) were previously detected in untreated CD 
children and particularly in treated CD patients with a GFD(7). These findings indicate that 10 
this dietary therapy may contribute to reducing beneficial bacterial group counts and 
increasing enterobacterial counts, which are microbial features associated with the active 
phase of CD(7,28) and, therefore, it would not favour completely the normalization of the gut 
ecosystem in treated CD patients. The relative proportion of F. prausnitzii was also 
significantly reduced after the GFD in healthy adults following a similar trend as that 15 
detected in untreated or treated CD patients compared with controls(7). A depletion of F. 
prausnitzii population in faecal mucus of active Crohn's disease patients has also been 
detected, leading to establish an inverse relation between the abundance of this population 
and inflammatory bowel disorders(29). Bifidobacterium species composition was also 
analysed under the effect of the GFD by qPCR (Table 3). Individual baseline variability of 20 
bacterial populations expressed as median of differences in log cells per gram of faeces 
(IQR) was as follows: 0.71 (0.08-1.33) for B. longum, 0.68 (0.07-1.03) for B. breve, 1.16 
(0.77-1.07) for B. bifidum, 0.86 (0.17-1.29) for B. adolescentis, 1.21 (0.63-1.72) for B. 
catenulatum, 0.30 (0.002-0.45) for B. angulatum and 0.35 (0.19-0.82) for B. lactis. The 
counts of B. angulatum were significantly increased (P=0.038) after the GFD, while those 25 
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of B. longum decreased (P=0.017), indicating that this species contributed to the reduction 
detected in total Bifidobacterium population (Table 3). The genome sequence of B. longum 
subsp. longum showed that more than 8% of the annotated genes were involved in 
carbohydrate and polysaccharide metabolism(30), which could explain the reduction of their 
levels after the GFD, paralleled to a reduction in polysaccharide intake.    5 
 
GFD influences immunostimulatory activity of the intestinal microbiota  
Changes in cytokine production patterns stimulated by faecal samples of healthy 
individuals after and before the GFD are shown in Fig. 1. Immunostimulatory properties of 
the colonic content of these individuals, representing an altered microbiota, were 10 
remarkably reduced after following a GFD, inducing a significantly lower production of the 
pro-inflammatory cytokines TNF-α (P =0.021) and IFN-γ (P =0.037), and the chemokine 
IL-8 (P=0.007). Thus, a GFD could contribute to reduce the pro-inflammatory signals in 
the gut by introducing modifications in the microbiota structure. In addition, the faecal 
samples of individuals under a GFD induced significantly lower production of the anti-15 
inflammatory cytokine IL-10 (P = 0.002) than those of individuals on a standard gluten-
containing diet. IL-10 inhibits the production of pro-inflammatory and Th1 cytokines such 
as TNF-α and IFN-γ(31). Therefore, it could be expected that reductions in Th1-type 
cytokine production were accompanied by increases in the Th2-type and regulatory 
cytokine IL-10. However, when a stimulus increases IFN-γ production, IL-10 production 20 
can also be increased by counter-regulatory mechanisms and vice versa. In this case, it 
seems likely that GFD led to a generalized reduction of bacterial-induced cytokine 
production in vitro as a result of the generalized reduction caused by this dietary 
intervention in the total luminal bacterial load of the large intestine. Moreover, specific 
bacterial group changes could also be partially responsible for the differences detected in 25 
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cytokine induction since, for instance, Bifidobacterium genus and particularly some B. 
longum strains have been acknowledged for their ability to stimulate IL-10 production (25) 
and their levels were significantly reduced after the GFD. The immune suppressive effects 
associated with the GFD may be partly beneficial for CD patients, which are prone to a 
Th1-biased immune response, but may also imply a defect of their defence and regulatory 5 
mechanisms against harmful antigens and chronic inflammation.  
 
Conclusions 
The obtained results suggest that a GFD may influence the composition and immune 
function of the gut microbiota in healthy individuals without the influence of any 10 
underlying disease paralleled to reductions in polysaccharide intake. Although this is a 
preliminary short-term intervention study, bacterial deviations are similar as those detected 
previously in children after compliance with a long-term GFD. As intestinal bacteria 
constitute a constant challenge of antigens to their host that modulate immunity, the GFD 
should be considered as a possible environmental factor that may shape the microbiota 15 
composition and gut health in treated CD patients.   
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Figure 1. Cytokine production by PBMCs stimulated with faecal samples from healthy 
volunteers before and after the gluten-free diet and controls (non-stimulated PBMCs). 
Results are expressed as mean ± SD of duplicates measures determined in four 5 
independent experiments. Statistically significant differences were established by 
applying Student’s t-test at P<0.050. 
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Table 1. Daily energy and nutrient intake before and after the gluten-free diet intervention. 
 
Subject before GFD 
n=10  
Subjects under GFD 
n=10 Diet composition 
Mean   SD Mean  SD 
Energy (kcal)  1854.61  345.82 1784.06  301.93 
Water (g) 2454.56  533.35 2764.96   464.18 
Protein (g) 72.99  15.69 68.48  13.19 
Energy from protein (%) 15.74 3.38 15.35 2.96 
Fat (g) 78.69  21.12 71.95  19.00 
Energy from fat (%) 38.19 10.25 36.30 9.58 
Saturated fat  (g) 23.21  11.17 22.42 6.55 
Energy from saturated fat (%) 11.26 5.42 11.31 3.30 
MUFA (g) 29.97  8.30 28.79   8.41 
Energy from MUFA (%) 14.54 4.03 14.52 4.24 
PUFA (g) 11.58  5.59 9.43  3.93 
Energy from PUFA (%) 5.62 2.71 4.76 1.98 
Cholesterol (mg) 262.36  181.37 266.76 115.07 
CH (g) 212.41  55.42 218.87 69.05 
Energy from CH (%) 45.81 11.95 49.07 15.48 
Simple CH (g) 74.30 37.72 72.03 28.05 
Energy from simple CH (%) 16.02 8.14 16.15 6.29 
Polysaccharides (g) ª 116.63  51.62 62.95  33.12 
Energy from complex CH (%) 25.15 11.13 14.11 7.43 
Dietary fiber (g) 19.52 10.78 17.56 9.13 
 
Abbreviations:  MUFA= Monounsaturated fatty acids, PUFA = Polyunsaturated fatty acids, CH = 
Carbohydrates 5 









Table 2. Composition of the faecal microbiota of healthy adults before and after following a gluten-free diet (GFD) analysed by fluorescent in situ 
hybridization and flow cytometry detection. 
 
Adults under standard diet 
(n=10) 
Adults under GFD diet 
(n=10) 
Mann-Whitney U test 
 Microbial group 
†Median IQR †Median IQR *P-value 
Atopobium 6.09 3.46-9.60 3.35 1.8-4.87                0.122 
Bifidobacterium 11.14 7.64-16.70 5.12 3.92-8.51 0.007* 
Lactobacillus-Enteroccoccus 2.58 1.34-3.50 0.78 0.56-2.66 0.058 
BacteroidesPrevotella 5.99 3.21-9.49 2.05 1.54-6.61 0.102 
E. coli 6.08 3.46-10.56 8.42 4.21-12.21 0.501 
E.rectale-C coccoides 6.56 4.19-20.15 4.52 1.81-9.77 0.122 
C.  histolyticum 7.87 3.99-12.01 6.93 3.72-10.47 0.753 
C. lituseburense 5.39 3.44-8.02 3.43 1.41-4.21  0.031* 
F. prausnitzii 13.77 8.37-17.98 5.08 4.41-7.20  0.009* 
†Data are shown as medians and interquartile range (IQR) of group-specific bacterial proportions related to total population detected with the EUB 
universal probe as determined by FCM-FISH.  




Table 3. Composition of the faecal microbiota of healthy adults before and after following a gluten-free diet (GFD) analysed by qPCR. 
Adults under standard diet 
(n=10) 




Pr †Median IQR Pr †Median IQR 
Mann-Whitney  U-test 
*P-value 
Bifidobacterium  10 8.85 7.84-9.24 10 7.79 7.43-8.45  0.020* 
Bacteroides 10 8.61 8.03-9.20 10 8.21 7.25-9.21 0.450 
C.coccoides 10 9.44 8.51-10.11 10 9.52 8.73-9.92 0.983 
C. leptum 10 9.54 9.18-10.31 10 10.11 9.81-10.52 0.141 
C. histolyticum 10 5.70 5.17-6.34 10 6.48 5.13-6.59 0.223 
Lactobacillus 10 7.73 7.10-7.98 10 7.00 6.25-7.64  0.001* 
E. coli 10 6.29 5.67-6.77 10 7.40 6.83-7.96  0.003* 
Enterobacteriaceae  10 6.64 5.86-7.99 10 8.16 7.41-8.42  0.005* 
Bifidobacterium species        
B. longum 10 7.73 7.61-8.62 10 7.32 6.54-7.79 0.017* 
B. breve 8 4.72 4.47-5.94 8 5.00 4.60-5.56 0.757 
B. bifidum 10 6.75 6.73-6.76 10 6.75 6.75-6.85 0.208 
B. adolescentis 7 5.71 4.83-8.65 8 6.73 5.39-7.80 0.975 
B. catenulatum 10 6.81 6.05-8.44 10 6.66 5.88-8.13 0.538 
B. angulatum 5 5.00 4.95-5.24 5 5.35 5.06-5.42   0.038* 
B. lactis 6 5.82 5.21-6.58 5 4.89 4.62-5.63 0.201 
†Data are shown as medians and interquartile range (IQR) of log of cell number per gram of faeces. 
⌠Pr (Prevalence) reflects the number of positive amplifications from total samples analysed by qPCR. 























































































































































































Figure 1. De Palma et al. 
